Overview

Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.
Details
Lead Sponsor:
Federal University of São Paulo
Treatments:
Cabergoline
Octreotide